Stocktoria
Bio Essence Corp BIOE
OTC · stock · Pharmaceutical Preparations · website · IPO 2022-03-30
Bio Essence Corp (BIOE) earns a Piotroski F-score of 9/9 (strong financial health). It does not currently pay a dividend. FY2025 revenue was $1.9M at a 47.2% net margin.
9/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Price from month-end closes (Yahoo) — for reference, not real-time.
Revenue trend · last 6y · up
How it ranks in Manufacturing · percentile among 1906 companies
Piotroski Fstronger than 100%
Net marginstronger than 98%
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 9/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| BIOE | Bio Essence Corp | 9/9 | — | 14.1 | — |
| LPCN | Lipocine Inc. | — | — | — | -82.3% |
| ORMP | ORAMED PHARMACEUTICALS INC. | 2/9 | 7.8 | 3 | — |
| DNTH | Dianthus Therapeutics, Inc. /DE/ | 1/9 | 14.17 | — | — |
| SXTC | China SXT Pharmaceuticals, Inc. | 3/9 | 2.19 | — | — |
| CYCN | Cyclerion Therapeutics, Inc. | 1/9 | — | — | — |
| CLSDQ | Clearside Biomedical, Inc. | 2/9 | — | — | — |
FAQ
Is BIOE financially healthy?
Bio Essence Corp's Piotroski F-score is 9/9 (8–9 is excellent, 0–3 weak).
Does BIOE pay a dividend?
No, Bio Essence Corp does not currently pay a dividend.
How profitable is BIOE?
In FY2025, Bio Essence Corp had a net margin of 47.2%.
Source: SEC EDGAR filings · CIK 0001723059 · US · as of 2025-12-31. facts plus Stocktoria's own computed scores — not investment advice.